Therefore, the magnitude of OS improvement supports clinicians to prescribe pertuzumab plus trastuzumab plus capecitabine for trastuzumab-treated HER2-positive advanced breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.